| アブストラクト | PURPOSE: Cyamemazine (Tercian((R))) is currently the most widely prescribed neuroleptic in France. This widespread use is due to its anxiolytics properties and to a claimed good safety profile. Although, prescription of cyamemazine is not devoid of the risks associated with the use of neuroleptics: extrapyramidal syndromes. This study aims at describing extrapyramidal syndromes induced by cyamemazine registered in the French pharmacovigilance database. METHODS: All spontaneous reports of extrapyramidal syndromes in the French pharmacovigilance database between 1st January 1985 and 31th December 2015 were described and analyzed. RESULTS: During this period 132 cases following cyamemazine intake were reported in the French pharmacovigilance database. The extrapyramidal syndromes were considered as "serious" in 77% of cases. More than 80% of the cases were described with a dosage of cyamemazine under 100mg/day and no correlation between drug dose and seriousness of the cases were found. Thirty-six cases were described with a monotherapy of cyamemazine. CONCLUSION: We should keep in mind that despite its widespread use in various indications (e.g. anxiolytic) cyamemazine remains a neuroleptic and could induce extrapyramidal syndromes even with low dosage. Careful monitoring should be performed when introducing and with long-term use of cyamemazine, mostly in elderly patients or patient already being treated with neuroleptics. |
|---|
| ジャーナル名 | Therapie |
|---|
| Pubmed追加日 | 2016/10/12 |
|---|
| 投稿者 | Khouri, Charles; Lepelley, Marion; Villier, Celine; Bougerol, Thierry; Mallaret, Michel |
|---|
| 組織名 | Centre regional de pharmacovigilance, CHU de Grenoble, pavillon E, CS 10217,;38043 Grenoble cedex 09, France. Electronic address: ckhouri@chu-grenoble.fr.;38043 Grenoble cedex 09, France.;Clinique de psychiatrie, pole neurologie psychiatrie, CHU de Grenoble, 38043;Grenoble, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/27726885/ |
|---|
